RxDoctor Payments Data

Stanley Chetcuti, MD

Cardiovascular Disease · Ann Arbor, MINPI 1467503516

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (46.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 94.3% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $155,691, 3.4 times the $46,050 reported in 2019. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$572,715in general payments, 2019–2025

Across 1,462 payments — averaging $391.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$540K
  • Abbott$13K
  • Boston Scientific$8K
  • Edwards Lifesciences$7K
  • Philips North America LLC$2K
  • Siemens Medical Solutions USA, Inc.$1K
  • plus $2K from 8 others
$3,813,638in research payments, 2019–2025

Across 766 payments — averaging $4978.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$1.9M
  • Edwards Lifesciences$874K
  • Boston Scientific$506K
  • W. L. Gore & Associates, Inc.$181K
  • Jenavalve Technology, Inc.$152K
  • Abbott$123K
  • plus $118K from 2 others

What the payments were for

  • Consulting fees$88,31915%
  • Speaking & faculty fees$264,17546%
  • Travel & lodging$166,83029%
  • Food & beverage$53,3859%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572,715 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$114,821
Medicare patients
258
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$36,429
Ranolazine ErRanolazine15$2,161
ClopidogrelClopidogrel Bisulfate99$1,752
Metoprolol Succinate72$1,422
Atorvastatin Calcium66$1,298
Rosuvastatin Calcium53$1,237
Ezetimibe20$737
Isosorbide Mononitrate ErIsosorbide Mononitrate21$437
Lisinopril45$386
Amlodipine Besylate44$339
Carvedilol18$199
Metoprolol Tartrate22$177
Nifedipine ErNifedipine11$171
Furosemide16$130
Hydrochlorothiazide19$126

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Ann Arbor

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →